Jivi and Rebinyn Will Be New Clotting Factors for Hemophilia

New clotting factor products, Jivi (JIH-vee) and Rebinyn (reh-bee-NYNE), will put more focus on hemophilia treatment.

Hemophilia patients have a genetic disorder where clotting factors VIII or IX are missing or don't work correctly. This leads to a high bleeding risk.

Be ready to handle orders for meds to prevent or stop bleeding in patients with hemophilia.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals